Tolerability and antidepressive effect of brofaromine, a short-acting reversible MAO inhibitor--an open study

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Medicine

Background:

• Selective monoamine oxidase A (MAO-A) inhibitors represent a class of antidepressants.
• Understanding the tolerability and efficacy of novel MAO-A inhibitors is crucial for treating depression.

Purpose of the Study:

• To evaluate the tolerability and antidepressant effects of brofaromine, a selective MAO-A inhibitor.
• To assess the safety profile of brofaromine in patients with depression.

Main Methods:

• A study involving 14 depressive patients.
• Administration of tyramine-enriched meals to assess cardiovascular response.
• Evaluation of antidepressive effectiveness using the Hamilton Depression Rating Scale (HAMD).

Main Results:

• No significant changes in blood pressure or pulse frequency were observed after tyramine ingestion.
• Four patients experienced agitation; two discontinued due to paranoid thinking and suicidal tendencies.
• Three patients reported sleep disturbances, specifically difficulty falling asleep.
• Significant improvement in depressive symptoms was noted from day 14 onwards on the HAMD scale.

Conclusions:

• Brofaromine demonstrates antidepressant efficacy in patients with depression.
• While generally safe regarding tyramine interaction, potential side effects include agitation and sleep disturbances.
• Further research may be warranted to optimize brofaromine's use and manage its side effects.